Sorrento announces publication of data in Cell Press Journal Med describing the discovery and preclinical efficacy of a broad-acting SARS-CoV-2 neutralizing antibody administered IV (STI-9167) or IN (STI-9199)

Sorrento Therapeutics, Inc.

SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the publication in Cell Press journal Medium of data detailing work related to the discovery and preclinical profiling of the activity of neutralizing antibodies STI-9167 against a large collection of SARS-CoV-2 variants, including some Omicron subvariants. Protection against illnesses linked to Omicron live in a preclinical challenge model was observed after administration of STI-9167 intravenously (IV) or after intranasal (IN) administration using an intranasal formulation of STI-9167 antibody, designated STI-9199.

A link to the publication is below:

https://www.cell.com/med/fulltext/S2666-6340(22)00321-X

About Sorrento Therapeutics, Inc.

Sorrento is a clinical and commercial-stage biopharmaceutical company developing novel therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. Sorrento’s multi-modal, multi-pronged approach to fighting cancer is enabled by its extensive immuno-oncology platforms, including key assets such as next-generation tyrosine kinase (“TKI”) inhibitors, fully human antibodies (“G-MAB™ library”), cell therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”) and oncolytic viruses (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and coronavirus vaccines, including STI-1558, COVISHIELD™ and COVIDROPS™; and diagnostic testing solutions, including COVIMARK™.

Sorrento’s commitment to therapies that improve the lives of patients is also demonstrated by our efforts to advance a non-opioid pain management small molecule (TRPV1 agonist), resiniferatoxin (“RTX”) and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a new viscous gel formulation of a corticosteroid widely used for epidural injections to treat lumbosacral radicular pain or sciatica, and to market the ZTlido® (topical lidocaine system) 1.8% for the treatment of postherpetic neuralgia (PHN) . RTX has been cleared for a phase II trial in intractable pain associated with cancer and a phase II trial in patients with osteoarthritis. Positive final results from the CLEAR program of the pivotal Phase III trial for SEMDEXA™, its new non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.

For more information, visit www.sorrentotherapeutics.com

Forward-looking statements

This press release and all statements made for and during any presentation or meeting contain forward-looking statements relating to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties. which could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding expectations regarding technologies and product candidates of Sorrento and its affiliates. The risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements include, but are not limited to: risks relating to the technologies and prospects of Sorrento and its subsidiaries, affiliates and partners and collaborations with partners; clinical development risks, including risks relating to the progress, timing, cost and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; the risks that the results of a clinical study may not meet any or all of the clinical study endpoints and that data generated from such studies may not support regulatory submission or approval; the risks that the results of prior tests, studies and trials will not be replicated in ongoing or future studies and trials; risks associated with the manufacture and supply of pharmaceutical products; the risks of using the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in executing its product candidate strategies; risks related to the global impact of COVID-19; and other risks described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission and Exchange Commission, including the risk factors set forth in those documents. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statements in this press release unless the law requires it.

Media and investor relations
Contact: Brian Cooley
E-mail: [email protected]

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVIMARK™ and Fujovee™ are registered trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ (SP-102) is a registered trademark of Semnur Pharmaceuticals, Inc. Proprietary name review by the FDA is pending.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2022 Sorrento Therapeutics, Inc. All rights reserved.

Comments are closed.